Dr. Amrein is a seasoned healthcare executive with more than 25 years of leadership and international experience across a variety of therapeutic areas. Prior to joining Stallergenes Greer, he was Managing Director and member of the Global Leadership Team at Advanced Clinical, a leading global contract research organisation. Dr. Amrein previously held positions of increasing responsibility, notably at Novartis, Abbott and Shire Takeda, where he accrued significant expertise in P&L leadership, specialising in commercial expansions, market entries, product launches, transformations, acquisitions, and integrations.

Dr. Amrein is Swiss and holds a PhD in Health Economics, Evidence Based Medicine and Quality of Life for Rare Diseases from the University of Southern Queensland (Australia), an MBA from INSEAD (France) and a Master of Physics from ETH Zurich (Switzerland).

Prior to Abbott, Valérie Benhamou served as Senior counsel for Bristol-Myers Squibb. Earlier in her career, she practiced at law firms and focused on healthcare matters. Valerie holds a master’s degree in Private law and a postgraduate diploma in Intellectual Property law from the University of Paris II. She has been a member of the Paris Bar since 1999.

Prior to joining Stallergenes Greer, he was Head of Finance for International at Shire, leading the creation of a new financial framework and supporting the company’s growth and expansion.

Prior to Shire, he held several country, regional and division-level financial roles at Merck Serono, including Head of Divisional Controlling for the Neurology, Fertility and Endocrinology business, Head of Commercial Europe Finance, Global Biotech Manufacturing Controller, Finance and Logistic Director.

He is Swiss and Italian and holds a Master’s Degree in Business and Economics from the Bocconi University in Milan, and a Business and Leadership Program MBA from MIT-Sloan.

Tibor joined Stallergenes Greer in 2016 as Global Head of Technical Operations before taking over as Head of the Americas in May 2018.

He previously spent eight years at Novartis where he held roles of increasing responsibility, most recently as the Global Operations Head, Tech Ops Manufacturing, Strategy and BDM&A where he headed Operations for Manufacturing Strategy and Business Development & Licensing within Global Technical Operations.

Prior to Novartis, Tibor Nemes held Engineering and Operations leadership roles at pharmaceutical and biotechnology companies including Novavax, Inc., Bristol-Myers Squibb Company, Elan Pharmaceuticals and Hypex, Inc.

Dominique held roles of increasing responsibility in the pharmaceutical industry, holding positions in sales, marketing and strategy at local, regional and global levels. 

Prior to joining Stallergenes Greer in 2012, Dominique Pezziardi gained his expertise in several therapeutic fields including fertility, growth hormones, diabetes, orphan diseases, cardiology and medical devices, within pharmaceutical companies including Ciba, Sanofi and Merck Serono.

He successfully managed global product launches, life cycle development plans, mature franchises relaunches, alliances with strategic partners or more recently, corporate strategy development.

He graduated from a business school in Bordeaux, France and trained in pharmaco-economy in Milano, Italy.

Dr Elena Rizova  has gained extensive expertise in drug development and the launch of new entities in dermatology, immunology, oncology, the central nervous system and infectious and cardiovascular diseases.  She has significant leadership experience and has led complex cross-country matrix teams in medical, clinical, regulatory affairs, pharmacovigilance as well as in medical information and communication. 

In her most recent role as VP and Head of the Intercontinental Region, she oversaw Biogen’s medical teams and neuroscience portfolio based in Switzerland. She previously served as Global Head of Medical Affairs for Dermatology at Sanofi Genzyme based in the US. Prior to joining Sanofi Genzyme, she held several leadership roles at Johnson & Johnson Innovation Asia Pacific, Janssen based in Europe and Asia , 3M Pharmaceutical  based in Europe and Galderma based in France. 

Dr Elena Rizova is a medical doctor and a board-certified dermatologist with a PhD in immunology. 

With more than 20 years of experience in the pharmaceutical industry, Julien Storaï was previously Chief Technical Officer at OM Pharma in Geneva (Switzerland), where he oversaw global industrial activities and was responsible for assuring the company’s internal and external long-term industrial strategy. He also held site head and manufacturing positions at Vifor Pharma and began his professional career at Sanofi in Vaccine Industrial Development. 

Julien Storaï holds a PhD in Industrial Microbiology, Biochemistry Engineer INSA (France), an MBA EM Lyon (France) and is certified Black Belt Six Sigma. 

He previously worked at Sogefi, an Italian automotive supplier, where he served as Vice President Human Resources. Throughout his career, he held positions of increasing responsibility and gained in-depth knowledge of human resources at automotive, airport ground handling and media companies. Jérôme Tilly holds a master's degree in business administration, employment law and Human Resources from Paris Dauphine University, France

Petr Tor gained his expertise in several therapeutic fields including asthma, cardio, diabetes, glaucom, antibiotics, antifungals and HIV within Merck & Co. known as MSD in Europe, where he spent 16 years.

He joined Stallergenes Greer as General Manager of the Czech and Slovak subsidiary and since 2014 he held commercial responsibilities for various regions with growing scope and complexity in Europe, Middle East and Africa.

He is Czech, graduated from Chemistry at Institute of Chemical Technology in Prague and got diploma in Accounting and Finance at MBA Rochester Institute of Technology, New York US Business School in Prague.